Inscription Capital LLC Acquires New Shares in IQVIA Holdings Inc. (NYSE:IQV)

Inscription Capital LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent filing with the SEC. The fund acquired 1,920 shares of the medical research company’s stock, valued at approximately $465,000.

Several other large investors also recently added to or reduced their stakes in the stock. Brown Brothers Harriman & Co. raised its stake in shares of IQVIA by 39.4% during the 2nd quarter. Brown Brothers Harriman & Co. now owns 760 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 215 shares during the period. Sigma Planning Corp purchased a new position in IQVIA during the second quarter worth about $722,000. Neuberger Berman Group LLC grew its position in IQVIA by 5.6% during the second quarter. Neuberger Berman Group LLC now owns 91,328 shares of the medical research company’s stock worth $21,937,000 after buying an additional 4,862 shares in the last quarter. Jump Financial LLC purchased a new position in IQVIA during the second quarter worth about $1,357,000. Finally, QS Investors LLC grew its position in IQVIA by 19.3% during the second quarter. QS Investors LLC now owns 6,781 shares of the medical research company’s stock worth $1,644,000 after buying an additional 1,096 shares in the last quarter. Institutional investors own 87.01% of the company’s stock.

Shares of NYSE:IQV opened at $241.51 on Thursday. IQVIA Holdings Inc. has a 52-week low of $150.65 and a 52-week high of $265.34. The firm has a market capitalization of $46.28 billion, a P/E ratio of 77.41, a P/E/G ratio of 1.84 and a beta of 1.43. The stock has a 50 day moving average price of $252.75 and a 200-day moving average price of $240.52. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.05 and a current ratio of 1.05.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 27th. The medical research company reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.07 by $0.06. The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.27 billion. IQVIA had a return on equity of 23.95% and a net margin of 4.69%. The business’s revenue was up 36.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 8.26 EPS for the current fiscal year.

IQV has been the subject of several recent analyst reports. Mizuho boosted their target price on IQVIA from $250.00 to $270.00 and gave the stock a “buy” rating in a research report on Wednesday, July 28th. Robert W. Baird upped their price objective on IQVIA from $273.00 to $285.00 and gave the stock an “outperform” rating in a report on Wednesday, July 28th. Piper Sandler upped their price objective on IQVIA from $204.00 to $235.00 and gave the stock a “neutral” rating in a report on Wednesday, July 28th. Morgan Stanley upped their price objective on IQVIA from $260.00 to $280.00 and gave the stock an “overweight” rating in a report on Wednesday, July 28th. Finally, Barclays upped their price objective on IQVIA from $260.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, July 13th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Buy” and an average price target of $262.33.

About IQVIA

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment provides mission critical information, technology solutions and real world solutions and services to the firm’s life science clients.

Featured Story: What is the Beige Book?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.